Inhibitors of hepatitis C virus NS3·4A protease 1. Non-Charged tetrapeptide variants
- 30 September 2003
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (22), 4059-4063
- https://doi.org/10.1016/j.bmcl.2003.08.050
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Recent developments in the discovery of hepatitis C virus serine protease inhibitors – towards a new class of antiviral agents?Expert Opinion on Investigational Drugs, 2003
- Capped dipeptide α-Ketoacid inhibitors of the HCV NS3 proteaseBioorganic & Medicinal Chemistry Letters, 2002
- Future therapy of hepatitis CHepatology, 2002
- Hepatitis C therapeutics: current status and emerging strategiesNature Reviews Drug Discovery, 2002
- Tetrapeptides as potent protease inhibitors of hepatitis C virus full-Length NS3 (Protease-Helicase/NTPase)Bioorganic & Medicinal Chemistry, 2002
- 5 Inhibitors of Hepatitis C Virus NS3•4A Protease: An Overdue Line of TherapyProgress in Medicinal Chemistry, 2002
- Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitorsBioorganic & Medicinal Chemistry Letters, 2000
- α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitorsBioorganic & Medicinal Chemistry Letters, 2000
- Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage ProductsBiochemistry, 1998
- Product Inhibition of the Hepatitis C Virus NS3 ProteaseBiochemistry, 1998